Thomas A Baillie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1739032/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The resurgence of covalent drugs. Nature Reviews Drug Discovery, 2011, 10, 307-317. | 46.4 | 1,384 |
| 2 | Drugâ^'Protein Adducts:Â An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. Chemical Research in Toxicology, 2004, 17, 3-16. | 3.3 | 707 |
| 3 | Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. Chemical Research in Toxicology, 2011, 24, 1345-1410. | 3.3 | 569 |
| 4 | Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery, 2011, 10, 292-306. | 46.4 | 382 |
| 5 | Targeted Covalent Inhibitors for Drug Design. Angewandte Chemie - International Edition, 2016, 55, 13408-13421. | 13.8 | 360 |
| 6 | Drug Metabolites in Safety Testing. Toxicology and Applied Pharmacology, 2002, 182, 188-196. | 2.8 | 344 |
| 7 | Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization. Drug Metabolism and Disposition, 2002, 30, 505-512. | 3.3 | 317 |
| 8 | Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scissionâ€. Chemical Research in Toxicology, 2001, 14, 62-70. | 3.3 | 316 |
| 9 | Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1042-1051. | 2.5 | 280 |
| 10 | Mass spectrometry in the analysis of glutathione conjugates. Biological Mass Spectrometry, 1993, 22, 319-325. | 0.5 | 232 |
| 11 | Negative Ion Tandem Mass Spectrometry for the Detection of Glutathione Conjugates. Chemical Research in Toxicology, 2005, 18, 630-638. | 3.3 | 210 |
| 12 | Biotransformation of the Naturally Occurring Isothiocyanate Sulforaphane in the Rat:Â Identification of Phase I Metabolites and Glutathione Conjugates. Chemical Research in Toxicology, 1997, 10, 1228-1233. | 3.3 | 202 |
| 13 | Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism. Chemical Research in Toxicology, 2008, 21, 129-137. | 3.3 | 193 |
| 14 | Cytochrome P450 3A4-Mediated Bioactivation of Raloxifene:  Irreversible Enzyme Inhibition and Thiol Adduct Formation. Chemical Research in Toxicology, 2002, 15, 907-914. | 3.3 | 169 |
| 15 | Future of ToxicologyMetabolic Activation and Drug Design:Â Challenges and Opportunities in Chemical Toxicology. Chemical Research in Toxicology, 2006, 19, 889-893. | 3.3 | 166 |
| 16 | Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenacâ€. Chemical Research in Toxicology, 1999, 12, 192-199. | 3.3 | 156 |
| 17 | Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 969-978. | 2.5 | 149 |
| 18 | Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo. Accounts of Chemical Research, 1991, 24, 264-270. | 15.6 | 139 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Integration of Knowledge-Based Metabolic Predictions with Liquid Chromatography Data-Dependent Tandem Mass Spectrometry for Drug Metabolism Studies:Â Application to Studies on the Biotransformation of Indinavir. Analytical Chemistry, 2004, 76, 823-832. | 6.5 | 133 |
| 20 | Metabolism of the Chemoprotective Agent Diallyl Sulfide to Glutathione Conjugates in Rats. Chemical Research in Toxicology, 1997, 10, 318-327. | 3.3 | 127 |
| 21 | Biotransformation of methyl isocyanate in the rat. Evidence for glutathione conjugation as a major pathway of metabolism and implications for isocyanate-mediated toxicities. Chemical Research in Toxicology, 1991, 4, 157-161. | 3.3 | 122 |
| 22 | Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. Journal of Medicinal Chemistry, 1986, 29, 2396-2399. | 6.4 | 117 |
| 23 | Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra- and Inter-Species Differences in Drug Metabolism. Drug Metabolism and Pharmacokinetics, 2011, 26, 15-29. | 2.2 | 114 |
| 24 | Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clinical Pharmacology and Therapeutics, 1990, 48, 225-235. | 4.7 | 113 |
| 25 | Highâ€throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole timeâ€ofâ€flight system as a â€~firstâ€line' approach for metabolite identification studies. Rapid Communications in Mass Spectrometry, 2008, 22, 1053-1061. | 1.5 | 108 |
| 26 | A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4. Journal of Biological Chemistry, 2001, 276, 2256-2262. | 3.4 | 107 |
| 27 | Organic Chemistry in Drug Discovery. Science, 2004, 303, 1810-1813. | 12.6 | 107 |
| 28 | Enzyme Kinetics of Cytochrome P450-Mediated Reactions. Current Drug Metabolism, 2012, 2, 17-36. | 1.2 | 100 |
| 29 | Metabolic interactions between mibefradil and HMG oA reductase inhibitors: an in vitro investigation with human liver preparations. British Journal of Clinical Pharmacology, 1999, 47, 291-298. | 2.4 | 96 |
| 30 | Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chemical Research in Toxicology, 1988, 1, 195-199. | 3.3 | 92 |
| 31 | An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway. Molecular Pharmacology, 2012, 81, 498-509. | 2.3 | 87 |
| 32 | Inhibition of medium-chain fatty acid β-oxidationinvitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochemical and Biophysical Research Communications, 1985, 132, 245-252. | 2.1 | 83 |
| 33 | Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicology and Applied Pharmacology, 2006, 217, 143-152. | 2.8 | 81 |
| 34 | In VitroStudies on the Metabolic Activation of the Furanopyridine L-754,394, a Highly Potent and Selective Mechanism-Based Inhibitor of Cytochrome P450 3A4. Chemical Research in Toxicology, 1996, 9, 1007-1012. | 3.3 | 79 |
| 35 | S-(N-Methylcarbamoyl)glutathione: A reactive S-linked metabolite of methyl isocyanate. Biochemical and Biophysical Research Communications, 1990, 166, 245-250. | 2.1 | 74 |
| 36 | Carbamoylation of peptides and proteins in vitro by S-(N-methylcarbamoyl)glutathione and S-(N-methylcarbamoyl)cysteine, two electrophilic S-linked conjugates of methyl isocyanate. Chemical Research in Toxicology, 1991, 4, 436-444. | 3.3 | 73 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 37 | The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews, 2013, 33, 985-1080. | 10.5 | 73 |
| 38 | Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. Journal of Medicinal Chemistry, 1985, 28, 997-1001. | 6.4 | 72 |
| 39 | Addressing Metabolic Activation as an Integral Component of Drug Design. Drug Metabolism Reviews, 2006, 38, 641-649. | 3.6 | 72 |
| 40 | Zafirlukast Metabolism by Cytochrome P450 3A4 Produces an Electrophilic α,β-Unsaturated Iminium Species That Results in the Selective Mechanism-Based Inactivation of the Enzyme. Chemical Research in Toxicology, 2005, 18, 1427-1437. | 3.3 | 69 |
| 41 | Identification of Novel Glutathione Conjugates of Disulfiram and Diethyldithiocarbamate in Rat Bile by Liquid Chromatography-Tandem Mass Spectrometry. Evidence for Metabolic Activation of Disulfiram in vivo. Chemical Research in Toxicology, 1994, 7, 526-533. | 3.3 | 68 |
| 42 | EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE. Drug Metabolism and Disposition, 2004, 32, 1254-1259. | 3.3 | 68 |
| 43 | In Vitro Bioactivation of Dihydrobenzoxathiin Selective Estrogen Receptor Modulators by Cytochrome P450 3A4 in Human Liver Microsomes:  Formation of Reactive Iminium and Quinone Type Metabolites. Chemical Research in Toxicology, 2005, 18, 675-685. | 3.3 | 68 |
| 44 | Monoacetylhydrazine as a metabolite of isoniazid in man. Clinical Pharmacology and Therapeutics, 1977, 22, 602-608. | 4.7 | 67 |
| 45 | Matrix-assisted laser desorption ionization for rapid determination of the sequences of biologically active peptides isolated from support-bound combinatorial peptide libraries. Rapid Communications in Mass Spectrometry, 1994, 8, 77-81. | 1.5 | 63 |
| 46 | Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chemico-Biological Interactions, 1994, 90, 253-275. | 4.0 | 62 |
| 47 | EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS. Drug Metabolism and Disposition, 2006, 34, 145-151. | 3.3 | 57 |
| 48 | The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation. Rapid Communications in Mass Spectrometry, 2003, 17, 81-86. | 1.5 | 55 |
| 49 | Identification in Rat Bile of Glutathione Conjugates of Fluoromethyl 2,2-Difluoro-1-(trifluoromethyl)vinyl Ether, a Nephrotoxic Degradate of the Anesthetic Agent Sevoflurane. Chemical Research in Toxicology, 1996, 9, 555-561. | 3.3 | 54 |
| 50 | Approaches to the Assessment of Stable and Chemically Reactive Drug Metabolites in Early Clinical Trials. Chemical Research in Toxicology, 2009, 22, 263-266. | 3.3 | 54 |
| 51 | Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discovery Today, 2005, 10, 711-717. | 6.4 | 52 |
| 52 | Electrospray tandem mass spectrometry in the diagnosis of organic acidemias. Rapid Communications in Mass Spectrometry, 1994, 8, 129-133. | 1.5 | 51 |
| 53 | In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations. Drug Metabolism and Disposition, 2008, 36, 469-473. | 3.3 | 50 |
| 54 | Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N,N'-bis(2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro. Chemical Research in Toxicology, 1993, 6, 376-383. | 3.3 | 48 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Metabolic Activation of a 1,3-Disubstituted Piperazine Derivative:Â Evidence for a Novel Ring Contraction to an Imidazoline. Chemical Research in Toxicology, 2005, 18, 271-276. | 3.3 | 45 |
| 56 | Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Communications in Mass Spectrometry, 2008, 22, 3510-3516. | 1.5 | 40 |
| 57 | Covalent binding of acetaminophen to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of the arylating metabolites. Chemico-Biological Interactions, 1988, 68, 99-116. | 4.0 | 39 |
| 58 | Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign. Angewandte Chemie, 2016, 128, 13606-13619. | 2.0 | 39 |
| 59 | Binding of flexible ligands to proteins: Valproic acid and its interaction with cytochrome P450cam. International Journal of Quantum Chemistry, 1993, 48, 161-180. | 2.0 | 36 |
| 60 | Safety Assessment of Acyl Glucuronides—A Simplified Paradigm. Drug Metabolism and Disposition, 2018, 46, 908-912. | 3.3 | 34 |
| 61 | Metabolism of valproate to hepatotoxic intermediates. Pharmaceutisch Weekblad Scientific Edition, 1992, 14, 122-125. | 0.9 | 32 |
| 62 | Applications of tandem mass spectrometry to the characterization of derivatized glutathione conjugates. Studies withS-(N-Methylcarbamoyl)-glutathione, a metabolite of the antineoplastic agentN-methylformamide. Biological Mass Spectrometry, 1988, 16, 51-56. | 0.5 | 29 |
| 63 | Reversibility in Glutathione-Conjugate Formation. Advances in Pharmacology, 1994, 27, 163-181. | 2.0 | 27 |
| 64 | Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEVâ€50717) Compared With Tetrabenazine in Healthy Volunteers. Clinical and Translational Science, 2020, 13, 707-717. | 3.1 | 25 |
| 65 | Recent Advances in the Use of Stable Isotopes in Drug Metabolism Research. Journal of Clinical Pharmacology, 1986, 26, 481-484. | 2.0 | 23 |
| 66 | Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites. Clinical Pharmacology and Therapeutics, 1986, 40, 172-177. | 4.7 | 22 |
| 67 | Approaches for Minimizing Metabolic Activation of New Drug Candidates in Drug Discovery. Handbook of Experimental Pharmacology, 2010, , 511-544. | 1.8 | 21 |
| 68 | The use of alkoxycarbonyl derivatives for the mass spectral analysis of drug-thioether metabolites. Studies with the cysteine, mercapturic acid and glutathione conjugates of acetaminophen. Biomedical & Environmental Mass Spectrometry, 1988, 15, 637-647. | 1.6 | 17 |
| 69 | Toxicity of the methyl isocyanate metabolite S-(N-methylcarbamoyl)GSH on mouse embryos in culture. Teratology, 1992, 46, 61-67. | 1.6 | 17 |
| 70 | Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opinion on Drug Discovery, 2021, 16, 275-287. | 5.0 | 17 |
| 71 | Application of liquid chromatography/thermospray mass spectrometry to studies on the formation of glutathione and cysteine conjugates from monomethylcarbamate metabolites of bambuterol. Rapid Communications in Mass Spectrometry, 1989, 3, 360-363. | 1.5 | 16 |
| 72 | In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants. Pharmaceutical Research, 1991, 08, 690-697. | 3.5 | 15 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Biotransformation and bioactivation reactions – 2015 literature highlights. Drug Metabolism Reviews, 2016, 48, 113-138. | 3.6 | 14 |
| 74 | Drug–protein adducts: past, present, and future. Medicinal Chemistry Research, 2020, 29, 1093-1104. | 2.4 | 14 |
| 75 | Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Current Opinion in Drug Discovery & Development, 2008, 11, 43-52. | 1.9 | 14 |
| 76 | Studies on the formation of reactive intermediates from the antineoplastic agentN,N′Bis(2-chloroethyl)-N-nitrosourea (BCNU)in vitro andin Vivo. Characterization of novel glutathione adducts by ionspray tandem mass spectrometry. Journal of Mass Spectrometry, 1995, 30, 57-68. | 1.6 | 13 |
| 77 | Metabolism of a Thiazole Benzenesulfonamide Derivative, a Potent and Selective Agonist of the Human β3-Adrenergic Receptor, in Rats: Identification of a Novel Isethionic Acid Conjugate. Drug Metabolism and Disposition, 2002, 30, 778-787. | 3.3 | 13 |
| 78 | Studies on the biotransformation of ketamine. Il—quantitative significance of theN-demethylation pathway in ratsin vivo determined by a novel stable isotope technique. Biomedical & Environmental Mass Spectrometry, 1989, 18, 401-404. | 1.6 | 12 |
| 79 | Identification of S-(n-Butylcarbamoyl)glutathione, a Reactive Carbamoylating Agent, as a Biliary Metabolite of Benomyl in the Rat. Journal of Agricultural and Food Chemistry, 1994, 42, 2953-2957. | 5.2 | 12 |
| 80 | Recognition of quaternary ammonium compounds using mass spectrometry. Rapid Communications in Mass Spectrometry, 1994, 8, 65-70. | 1.5 | 11 |
| 81 | 2-acetamido-p-benzoquinone: A reactive arylating metabolite of 3'-hydroxyacetanilide. Biochemical Pharmacology, 1985, 34, 2871-2876. | 4.4 | 9 |
| 82 | Drug Biotransformation: Mechanistic Studies With Stable Isotopes. Journal of Clinical Pharmacology, 1986, 26, 448-451. | 2.0 | 9 |
| 83 | Evidence for thein vitro metabolism of allylisopropylacetamide to reactive intermediates. Mechanistic studies with oxygen-18. Biomedical Mass Spectrometry, 1984, 11, 320-331. | 1.9 | 8 |
| 84 | Minimizing the potential for metabolic activation as an integral part of drug design. Current Opinion in Drug Discovery & Development, 2005, 8, 44-50. | 1.9 | 7 |
| 85 | Synthesis and characterization of isotopically-labelled cysteine- and glutathione conjugates of methylisocyanate. Journal of Labelled Compounds and Radiopharmaceuticals, 1989, 27, 1371-1382. | 1.0 | 6 |
| 86 | The contributions of Sidney D. Nelson to drug metabolism research. Drug Metabolism Reviews, 2015, 47, 4-11. | 3.6 | 6 |
| 87 | Improved detection of glucuronide and glutathione conjugates with thermospray ionization following esterification. Rapid Communications in Mass Spectrometry, 1994, 8, 371-376. | 1.5 | 3 |
| | | | |

88 Managing Metabolic Activation Issues in Drug Discovery. , 2019, , 577-603.